Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity
- 19 October 2006
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 63 (4), 477-487
- https://doi.org/10.1111/j.1365-2125.2006.02781.x
Abstract
We investigated flurbiprofen pharmacokinetics in 12 volunteers to develop a phenotypic trait measure that correlates with the fractional clearance to 4'-hydroxyflurbiprofen. The effect of the CYP2C9 inhibitor fluconazole on flurbiprofen metabolism was also evaluated. Flurbiprofen pharmacokinetics were evaluated before and after the first and seventh doses of fluconazole. The urinary recovery ratio was calculated as FLRR = 4'-OHF/[4'-OHF + F(tot)] and the urinary metabolic ratio was calculated as FLMR = 4'-OHF/F(tot), where 4'-OHF and F(tot) represent total (conjugated and unconjugated) amounts recovered in urine. There was a statistically significant relationship between the 4'-OHF formation clearance (4OHCLf) and both the 8-h FLRR and the 8-h FLMR with and without administration of fluconazole. The flurbiprofen apparent oral clearance (CL/F) was decreased by 53% [90% confidence interval (CI) -58, -48] and 64% (90% CI -69, -59), respectively, after administration of one and seven doses of fluconazole when compared with administration of flurbiprofen alone; similarly, the 4OHCLf decreased by 69% (90% CI -74, -64) and 78% (90% CI -83, -73), the 8-h FLRR decreased by 35% (90% CI -41, -29) and 40% (90% CI -46, -35) and the 8-h FLMR decreased by 61% (90% CI -65, -58) and 67% (90% CI -70, -63). The magnitude of decrease in CL/F and 4OHCLf was greater after seven doses compared with after one dose of fluconazole (P < 0.005). This study provides strong evidence that both the 8-h FLRR and the 8-h FLMR are suitable phenotypic indices for CYP2C9 activity.Keywords
This publication has 52 references indexed in Scilit:
- DETECTION OF A NOVEL REACTIVE METABOLITE OF DICLOFENAC: EVIDENCE FOR CYP2C9-MEDIATED BIOACTIVATION VIA ARENE OXIDESDrug Metabolism and Disposition, 2005
- Evaluation of Phenytoin Dosage Regimens Based on Genotyping of CYP2C Subfamily in Routinely Treated Japanese Patients††Financial support: This work was supported in part by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Sciences (JSPS).Drug Metabolism and Pharmacokinetics, 2005
- Evidence for the Benefits of the Low-Molecular-Weight Heparin Dalteparin in ‘High-Risk’ Patients with Acute Coronary SyndromesHeart Drug, 2004
- KIIV, AN IN VIVO PARAMETER FOR PREDICTING THE MAGNITUDE OF A DRUG INTERACTION ARISING FROM COMPETITIVE ENZYME INHIBITIONPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2003
- Polymorphic Variants (CYP2C9*3 and CYP2C9*5) and the F114L Active Site Mutation of CYP2C9: Effect on Atypical Kinetic Metabolism ProfilesDrug Metabolism and Disposition, 2002
- Effects of the Antifungal Agents on Oxidative Drug MetabolismClinical Pharmacokinetics, 2000
- Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivoBritish Journal of Clinical Pharmacology, 1996
- P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclaturePharmacogenetics, 1996
- Clinical Pharmacokinetics of Flurbiprofen and its EnantiomersClinical Pharmacokinetics, 1995
- Influence of H2 Receptor Antagonists on the Disposition of Flurbiprofen EnantiomersThe Journal of Clinical Pharmacology, 1990